Humoral response to Pfizer mRNA vaccine against SARS CoV2, in patients with autoimmune inflammatory rheumatic diseases and the impact on the rheumatic disease activity

Yolanda Braun-Moscovici, Marielle Kaplan, Doron Markovits, Samy Giryes, Kochava Toledano, Yonit Tavor, Katya Dolnikov, Alexandra Balbir-Gurman
doi: https://doi.org/10.1101/2021.04.02.21254493

Article Information

doi 
https://doi.org/10.1101/2021.04.02.21254493
History 
  • April 6, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Yolanda Braun-Moscovici1,3,*,
  2. Marielle Kaplan2,3,
  3. Doron Markovits1,3,
  4. Samy Giryes1,3,
  5. Kochava Toledano1,3,
  6. Yonit Tavor1,3,
  7. Katya Dolnikov1,3 and
  8. Alexandra Balbir-Gurman1,3
  1. 1B Shine Rheumatology Institute, Rambam Health Care Campus
  2. 2Biochemistry Laboratory, Rambam Health Care Campus
  3. 3Rappaport Faculty of Medicine, Technion, Haifa, Israel
  1. ↵*Corresponding author; email: y_braun{at}rambam.health.gov.il
Back to top
Posted April 06, 2021.
Download PDF
Data/Code
Email
Humoral response to Pfizer mRNA vaccine against SARS CoV2, in patients with autoimmune inflammatory rheumatic diseases and the impact on the rheumatic disease activity
Yolanda Braun-Moscovici, Marielle Kaplan, Doron Markovits, Samy Giryes, Kochava Toledano, Yonit Tavor, Katya Dolnikov, Alexandra Balbir-Gurman
medRxiv 2021.04.02.21254493; doi: https://doi.org/10.1101/2021.04.02.21254493
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area